Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01996202 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01996202 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 24 participants.
The verdict
NCT01996202, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a pilot study assessing the safety of the combination of ipilimumab administered concurrently with radiotherapy for patients with locally advanced or unresectable melanoma and patients at high risk for recurrence after resection.
Interventions
- RADIATION Radiation
- DRUG Ipilumimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-11 |
| Est. Completion | 2018-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01996202
The ClinicalTrials.gov registry entry for NCT01996202 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Radiation is the first listed.
NCT01996202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01996202 about?
NCT01996202 is a clinical study titled "A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma". This is a pilot study assessing the safety of the combination of ipilimumab administered concurrently with radiotherapy for patients with locally advanced or unresectable melanoma and patients at high risk for recurrence after resection.
What is the current status of trial NCT01996202?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-11. Estimated completion is 2018-09.
What interventions are being tested in trial NCT01996202?
The interventions under investigation include: Radiation (RADIATION), Ipilumimab (DRUG).
Who is sponsoring clinical trial NCT01996202?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.